New Tool for Reconstituting Factor VIII for Hemophilia A Prophylaxis
Simplifying factor VIII reconstitution may increase treatment adherence and satisfaction in patients with hemophilia A.
Hemophilia
Advances in the Treatment of Hemophilia: Clinical Gene Therapy
Gene therapy with adeno-associated viral viruses could provide an efficacious, safe, and cost-effective treatment option for patients with hemophilia.
Esperoct Approval Provides New Treatment Option for Hemophilia A
Novo Nordisk announced that the Food and Drug Administration (FDA) has approved Esperoct (turoctocog alfa pegol, N8-GP) for the treatment of patients with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis to reduce the frequency of bleeding episodes, on-demand treatment and control of bleeding episodes and perioperative management of bleeding.
Long-Term Outcome Profile in Patients With Acquired Hemophilia A
Underlying lymphoproliferative syndromes, male gender, and older age may be predictive of relapse in patients with acquired hemophilia A.
Episodic Treatment Compared With Prophylaxis in Patients With Hemophilia A
Researchers assessed safety outcomes in patients with hemophilia A without inhibitors.
Pharmacokinetics-Based Hemophilia A Prophylaxis May Improve Clinical Outcomes
Researchers assessed the influence of adopting population pharmacokinetics to inform prophylaxis for patients with hemophilia A.
Improving the Clinical Diagnosis of Inherited Bleeding Disorders
Many unique challenges surround the diagnosis and treatment of inherited mild bleeding disorders.
FDA Approves Updated Labeling for Hemophilia A Treatment Novoeight
The indication has been changed from “control and prevention of bleeding episodes” to “on-demand treatment and control of bleeding episodes” in adults and children with hemophilia A.
Advances in Treatment and Prevention of Hemophilia A: Takeaways From the 2018 ASH Annual Meeting
Research presented at the 2018 ASH Annual Meeting provided insights into the role of factor VIII as a therapeutic agent for severe hemophilia A.
Factor VIII, Factor IX Levels May Have Predictive Value in Identifying Severity of Hemophilia
Residual plasma levels of clotting factor XIII or factor IX accounted for around 70% of bleeding phenotype in patients with clinically severe hemophilia.
Next post in Bleeding Disorders
